



LJMU Research Online

Brandt, SD, Carlino, L, Kavanagh, PV, Westphal, F, Dreiseitel, W, Dowling, G, Baumann, MH, Sitte, HH and Halberstadt, AL

Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[b]thiophene (APBT) based stimulants

<http://researchonline.ljmu.ac.uk/id/eprint/12858/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Brandt, SD, Carlino, L, Kavanagh, PV, Westphal, F, Dreiseitel, W, Dowling, G, Baumann, MH, Sitte, HH and Halberstadt, AL (2020) Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[b]thiophene (APBT) based stimulants. *Drug Testing and Analysis*. 12 (8). pp. 1109-1125.

LJMU has developed [LJMU Research Online](http://researchonline.ljmu.ac.uk/) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[*b*]thiophene (APBT) based stimulants

Simon D. Brandt,^{1,*} Laura Carlino,^{1,2} Pierce V. Kavanagh,³ Folker Westphal,⁴ Wolfgang Dreiseitel,⁵ Geraldine Dowling,^{3,6} Michael H. Baumann,⁷ Harald H. Sitte,⁸ Adam L. Halberstadt^{9,10}

¹ School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK

² School of Chemical Engineers, University of Upper Alsace, 68093 Mulhouse, France

³ Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin 8, Ireland

⁴ State Bureau of Criminal Investigation Schleswig-Holstein, Section Narcotics/Toxicology, Mühlenweg 166, D-24116 Kiel, Germany

⁵ Hessian State Bureau of Criminal Investigation, Hölderlinstraße 1–5, Wiesbaden, Germany

⁶ Department of Life Sciences, School of Science, Sligo Institute of Technology, Ash Lane, Sligo, F91YW50, Ireland


⁷ Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA

⁸ Medical University of Vienna, Center for Physiology and Pharmacology, Institute of Pharmacology, Währinger Straße 13a, A-1090 Vienna, Austria.


⁹ Department of Psychiatry, University of California San Diego, La Jolla, CA 92093-0804, USA

¹⁰ Research Service, VA San Diego Healthcare System, La Jolla, CA, USA

* Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E-Mail: s.brandt@ljmu.ac.uk



Content	Page
NMR data of nitrostyrene intermediates (2-, 3-, 5-, and 6-APBT)	S3
EI mass spectra of all six APBT isomers	S4
Alternative suggestions for formations of m/z 147 and m/z 97 (EI-MS)	S5
EI-QqQ-MS/MS spectra of all six APBT isomers using m/z 147 as precursor ion	S6
Proposed fragmentation pathways (EI-MS/MS of m/z 147)	S7
Proposed fragmentation pathways (CI-MS)	S8
CI-QqQ-MS/MS spectra of all six APBT isomers using m/z 149 as precursor ion	S9
Proposed fragmentation pathways (CI-MS/MS of m/z 149)	S10
CI-QqQ-MS/MS spectra of all six APBT isomers using m/z 175 as precursor ion	S11
Proposed fragmentation pathways (CI-MS/MS of m/z 175)	S12
CI-QqQ-MS/MS spectra of all six APBT isomers using m/z 177 as precursor ion	S13
Proposed fragmentation pathways (CI-MS/MS formation of m/z 149 from m/z 177)	S13
Proposed fragmentation pathways (CI-MS/MS of m/z 177)	S14
Proposed fragments and fragmentation pathways of acetamido and HFB derivatives (GC-MS)	S15
Proposed fragments and fragmentation pathways of ethoxycarbonyl and methanesulfonamide derivatives (GC-MS)	S16
ESI single quadrupole mass spectra (in-source CID) of all six APBT isomers and experimental conditions	S17
QTOF tandem mass spectra of all six APBT isomers	S18
Calculated masses and molecular formulae obtained from QTOF-MS/MS and proposed fragmentation schemes for some ions derived from 4-, 5-, and 7-APBT	S19
HPLC-DAD UV spectra of all six APBT isomers	S20
NMR spectra of 2-APBT HCl (^1H , $^1\text{H}/^1\text{H}$ COSY, ^{13}C DEPTQ, HSQC and HMBC)	S21–S25
NMR spectra of 3-APBT HCl (^1H , $^1\text{H}/^1\text{H}$ COSY, ^{13}C DEPTQ, HSQC and HMBC)	S26–S30
NMR spectra of 4-APBT HCl (^1H , $^1\text{H}/^1\text{H}$ COSY, ^{13}C , HSQC and HMBC)	S31–S35
NMR spectra of 5-APBT HCl (^1H , $^1\text{H}/^1\text{H}$ COSY, ^{13}C DEPTQ, HSQC and HMBC)	S36–S40
NMR spectra of 6-APBT HCl (^1H , $^1\text{H}/^1\text{H}$ COSY, ^{13}C DEPTQ, HSQC and HMBC)	S41–S45
NMR spectra of 7-APBT HCl (^1H , $^1\text{H}/^1\text{H}$ COSY, ^{13}C , HSQC and HMBC)	S46–S50
IR spectra of 2-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)	S51–S53
IR spectra of 3-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)	S54–S56
IR spectra of 4-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)	S57–S59
IR spectra of 5-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)	S60–S62
IR spectra of 6-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)	S63–S65
IR spectra of 7-APBT (ATR-IR HCl, ATR-IR base, GC-sIR)	S66–S68
IR table: including aromatic ring C-C stretches; aromatic ring C-H in-plane bends; aromatic C-H out-of-plane bends	S69
GC-sIR partial spectra: overtone bands ($\sim 1700\text{--}2000\text{ cm}^{-1}$)	S70
GC-sIR partial spectra: 2- and 3-APBT	S71
GC-sIR partial spectra: 4- and 7-APBT	S72
GC-sIR partial spectra: 5- and 6-APBT	S73









Isomer	2		3		5		6	
Position	¹ H	¹³ C	¹ H	¹³ C	¹ H	¹³ C	¹ H	¹³ C
2	-	134.90	7.70 (s)	129.03	7.56 (d, <i>J</i> = 5.4 Hz)	128.06	7.59 (d, <i>J</i> = 5.4 Hz)	129.28
3	7.68 (s)	132.07	-	128.23	7.42 (d, <i>J</i> = 5.4 Hz)	124.00	7.38 (d, <i>J</i> = 5.4 Hz)	123.82
3a	-	138.62 or 141.94	-	138.30	-	139.92	-	140.23
4	7.91–7.86 (m)	124.75	7.91 (dist. d, <i>J</i> = 7.8 Hz)	121.77	7.91 (s)	125.46 or 125.48	7.88 (d, <i>J</i> = 8.3 Hz)	123.98
5	7.49–7.43 (m)	126.66 or 125.28	7.54–7.51 (m)	125.14 or 125.15	-	128.56	7.44 (dd, <i>J</i> = 8.3, 1.4 Hz)	125.95
6	7.49–7.43 (m)	126.66 or 125.28	7.50–7.47 (m)	125.52	7.42 (dd, <i>J</i> = 8.4, 1.6 Hz)	125.46 or 125.48	-	128.43
7	7.91–7.86 (m)	122.35	7.94 (dist. d, <i>J</i> = 7.8 Hz)	122.92	7.97 (d, <i>J</i> = 8.4 Hz)	123.01	7.97 (s)	124.43
7a	-	138.62 or 141.94	-	139.51	-	141.29	-	140.63
8	8.37–8.36 (m)	127.73	8.38–8.37 (m)	125.14 or 125.15	8.25 (s)	133.98	8.22 (s)	133.83
9	-	146.17	-	148.28	-	147.37	-	147.37
10	2.66 (d, <i>J</i> = 0.4 Hz)	14.28	2.57 (d, <i>J</i> = 0.8 Hz)	14.70	2.54 (d, <i>J</i> = 1.0 Hz)	14.19	2.53 (d, <i>J</i> = 0.9 Hz)	14.26




Table 1. NMR data for nitrostyrene intermediates (CDCl₃, 600/150 MHz).

Supporting Information – Drug Testing and Analysis







Electron ionization mass spectra of APBT isomers



Alternative suggestions for m/z 147 and m/z 97 (EI-MS)





Supporting Information – Drug Testing and Analysis



Supporting Information – Drug Testing and Analysis




EI-MS/MS of m/z 147

4-, 5-, 6-, 7-APBT




Supporting Information – Drug Testing and Analysis


CI-MS analysis



Supporting Information – Drug Testing and Analysis




* m/z 93: possibly from an ethyl phthalate?






Supporting Information – Drug Testing and Analysis







CI-MSMS of m/z 149






5-APBT









Supporting Information – Drug Testing and Analysis




CI-MSMS of m/z 175



Supporting Information – Drug Testing and Analysis




CI-MSMS m/z 149 from m/z 177




Supporting Information – Drug Testing and Analysis

CI-MSMS m/z 177




Supporting Information – Drug Testing and Analysis

AC derivatives





HFB derivatives




Supporting Information – Drug Testing and Analysis

EC derivatives




ion 121/ion 115 ratio

2	0.35
3	0.31
4	1.49
5	2.03
6	1.91
7	1.60




MSA derivatives









Supporting Information – Drug Testing and Analysis

In-source CID mass spectra - liquid chromatography electrospray ionization mass spectrometry

This consisted of an Agilent 1100 LC system coupled to a Hewlett Packard/Agilent 1100 MSD (Santa Clara, CA, USA). The following conditions were used: capillary voltage 3500 V, drying gas (N₂) 12 L/min at 350 °C and nebulizer (N₂) pressure 50 psig. The mass spectrometer was tuned according to the manufacturer's instructions using ESI Tuning Mix G2421A (Agilent Technologies). Chromatography was performed using an Allure PFP Propyl column (5 μm, 50 x 2.1 mm; Restek, Bellefonte, PA, USA): eluent A – methanol containing 0.1% formic acid, eluent B – water containing 0.1% formic acid); 20 % A (0 - 2 min.) followed by a linear gradient up to 80 % A at 22 min, 80 % A for 1 min, linear gradient down to 20 % A at 25 min, 20 % A for 5 min (run-time 30 min); flow rate of 600 μL/min, 10 μL of a 50 μg/mL injected. The mass spectrometer was run in ESI mode (m/z 70–500, with a fragmentor voltage set at 90 V for in-source CID).




Supporting Information – Drug Testing and Analysis




Supporting Information – Drug Testing and Analysis

Calc. m/z	Formula	2-APBT		3-APBT		4-APBT		5-APBT		6-APBT		7-APBT	
		Obs. m/z	Δ (ppm)	Obs. m/z	Δ (ppm)	Obs. m/z	Δ (ppm)	Obs. m/z	Δ (ppm)	Obs. m/z	Δ (ppm)	Obs. m/z	Δ (ppm)
192.0842	$C_{11}H_{14}NS^+$	192.0842	0	192.0842	0	192.0842	0	192.0842	0	No $[M+H]^+$		192.0842	0
175.0576	$C_{11}H_{11}S^+$	175.0576	0	175.0576	0	175.0576	0	175.0576	0	175.0576	0	175.0576	0
160.03412	$C_{10}H_8S^+$	–	–	160.03412	0	–	–	–	–	–	–	–	–
149.0420	$C_9H_9S^+$	149.0420	0	–	–	–	–	–	–	–	–	–	–
147.0263	$C_9H_7S^+$	–	–	147.0263	0	147.0263	0	147.0263	0	147.0263	0	147.0263	0
142.0777	$C_{11}H_{10}^{+}$	–	–	–	–	142.0777	0	142.0777	0	–	–	–	–
135.0263	$C_8H_7S^+$	–	–	–	–	–	–	135.0263	0	–	–	–	–
134.0185	$C_8H_6S^{+}$	134.0185	0	134.0185	0	–	–	–	–	–	–	–	–
58.0651	$C_3H_8N^+$	–	–	–	–	–	–	–	–	–	–	58.0651	0
44.0495	$C_2H_6N^+$	44.0495	0	44.0495	0	–	–	–	–	–	–	–	–


4- and 5-APBT



5-APBT









7-APBT



Proposed fragments related to 2-APBT and 3-APBT shown in main text of manuscript


Supporting Information – Drug Testing and Analysis

HPLC-DAD UV spectra





Supporting Information – Drug Testing and Analysis

2-APBT HCl
¹H-NMR (600 MHz)
 d₆-DMSO




Supporting Information – Drug Testing and Analysis

2-APBT HCl
COSY (600 MHz)
d₆-DMSO






Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

2-APBT HCl
HSQC
d₆-DMSO





Supporting Information – Drug Testing and Analysis

2-APBT HCl
HMBC
d₆-DMSO





Supporting Information – Drug Testing and Analysis

3-APBT HCl
¹H-NMR (600 MHz)
d₆-DMSO




Supporting Information – Drug Testing and Analysis

3-APBT HCl
COSY (600 MHz)
d₆-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

3-APBT HCl
HSQC
d₆-DMSO




Supporting Information – Drug Testing and Analysis

3-APBT HCl
HMBC
d₆-DMSO



Supporting Information – Drug Testing and Analysis


4-APBT HCl
¹H-NMR (600 MHz)
 d₆-DMSO



8.31
 7.92
 7.84
 7.83
 7.77
 7.76
 7.76
 7.34
 7.32
 7.25
 7.24



3.50
 3.50
 3.48
 3.47
 3.46
 3.45
 3.44
 3.43
 3.43
 3.42
 3.42
 3.40
 3.33
 3.03
 3.01
 3.01
 2.99

1.15
 1.13




Supporting Information – Drug Testing and Analysis

4-APBT HCl
COSY (600 MHz)
d₆-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

4-APBT HCl
HSQC
d₆-DMSO




Supporting Information – Drug Testing and Analysis

4-APBT HCl
HMBC
d₆-DMSO





Supporting Information – Drug Testing and Analysis




Supporting Information – Drug Testing and Analysis

5-APBT HCl
COSY (600 MHz)
d₆-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

5-APBT HCl
HSQC
d₆-DMSO





Supporting Information – Drug Testing and Analysis

5-APBT HCl
HMBC
d₆-DMSO





Supporting Information – Drug Testing and Analysis

6-APBT HCl
¹H-NMR (600 MHz)
 d₆-DMSO




Supporting Information – Drug Testing and Analysis

6-APBT HCl
COSY (600 MHz)
d₆-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

6-APBT HCl
HSQC
d₆-DMSO





Supporting Information – Drug Testing and Analysis

6-APBT HCl
HMBC
d₆-DMSO





Supporting Information – Drug Testing and Analysis

7-APBT HCl
¹H-NMR (600 MHz)
 d₆-DMSO




Supporting Information – Drug Testing and Analysis

7-APBT HCl
COSY (600 MHz)
d₆-DMSO





Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis

7-APBT HCl
HSQC
d₆-DMSO





Supporting Information – Drug Testing and Analysis


7-APBT HCl
HMBC
d₆-DMSO





2-APBT HCl – ATR-IR




2-APBT base – ATR-IR




2-APBT base – GC-sIR




3-APBT HCl – ATR-IR




3-APBT base – ATR-IR




3-APBT base – GC-sIR





4-APBT HCl – ATR-IR




4-APBT base – ATR-IR





4-APBT base – GC-sIR




5-APBT HCl – ATR-IR




5-APBT base – ATR-IR





5-APBT base – GC-sIR





6-APBT HCl – ATR-IR




6-APBT base – ATR-IR




6-APBT base – GC-sIR





7-APBT HCl – ATR-IR



7-APBT base – ATR-IR



7-APBT base – GC-sIR



Supporting Information – Drug Testing and Analysis




Isomer		Aromatic ring C-C stretches (1400–1500, 1585–1600 cm ⁻¹)	Aromatic ring C-H in-plane bends (1000–1250 cm ⁻¹)*	Aromatic C-H out-of-plane bends (675–900 cm ⁻¹)**
2	HCl (ATR-IR)	1430.5, 1456.4, 1496.9, 1575.2, 1602.0	1005.3, 1015.0, 1066.1, 1088.5, 1111.7, 1124.0, 1154.3, 1197.4, 1251.1, 1228.5, 1253.9	709.2, 726.8, 756.1, 811.3, 844.2
	Base (ATR-IR)	1435.1, 1456.6, 1569.5	1014.8, 1066.3, 1120.0, 1132.8, 1155.5, 1187.3	707.9, 725.9, 743.5, 813.2, 858.5
	Base (GC-sIR)	1437.3, 1458.3, 1538.7, 1581.6	1015.9, 1066.6, 1120.7, 1133.4, 1155.4, 1183.6, 1215.1, 1255.3	708.1, 728.1, 749.1, 812.7, 861.7
3	HCl (ATR-IR)	1425.5, 1459.0, 1515.1, 1539.1, 1568.5, 1592.7	1021.4, 1043.6, 1092.8, 1130.5, 1156.3, 1210.1, 1243.3, 1262.8	703.4, 736.9, 759.1, 767.6, 781.7, 834.1, 842.6
	Base (ATR-IR)	1426.1, 1457.6, 1576.9	1020.1, 1038.8, 1095.1, 1137.6, 1157.0, 1221.0, 1261.3	705.5, 730.3, 756.3, 766.9, 829.7
	Base (GC-sIR)	1427.4, 1459.0, 1580.3	1020.7, 1038.4, 1075.1, 1095.6, 1110.8, 1135.5, 1157.3, 1197.4, 1261.6	705.1, 733.9, 758.8, 769.0, 827.3, 874.4
4	HCl (ATR-IR)	1411.8, 1450.9, 1461.9, 1515.9, 1569.4, 1589.7	1055.1, 1091.0, 1117.7, 1129.2, 1155.4, 1167.4, 1209.1, 1239.5, 1257.9	690.8, 710.3, 758.9, 798.5, 860.3
	Base (ATR-IR)	1412.2, 1450.9, 1570.5	1053.9, 1088.0, 1164.3, 1203.3	689.3, 702.4, 758.4, 796.1, 818.1, 860.3
	Base (GC-sIR)	1413.2, 1452.3, 1582.9	1048.8, 1085.2, 1132.4, 1150.2, 1163.8, 1205.1, 1252.2	689.4, 703.7, 762.2, 796.3, 829.5, 861.4
5	HCl (ATR-IR)	1421.0, 1437.7, 1499.6, 1605.0	1000.8, 1021.6, 1050.4, 1085.4, 1128.8, 1145.5, 1211.0, 1224.8, 1251.0	694.6, 714.3, 770.0, 798.9, 836.5
	Base (ATR-IR)	1421.6, 1435.7, 1455.7, 1570.9	1050.1, 1089.0, 1145.7, 1159.7, 1224.2, 1261.4	689.5, 703.4, 754.7, 769.1, 800.8, 831.9, 894.0
	Base (GC-sIR)	1421.5, 1437.0, 1504.9, 1581.4, 1605.4	1051.0, 1072.5, 1089.0, 1109.9, 1134.4, 1146.0, 1159.5, 1224.9, 1261.7	690.5, 705.5, 756.9, 768.9, 801.8, 832.7, 868.3, 895.2
6	HCl (ATR-IR)	1466.2, 1497.1, 1570.9, 1617.6	1015.7, 1050.2, 1085.5, 1126.4, 1144.4, 1202.6, 1245.1	702.4, 716.5, 763.2, 787.2, 806.2, 840.2, 889.4
	Base (ATR-IR)	1439.0, 1462.5, 1478.8, 1571.7	1047.5, 1083.3, 1093.2, 1185.5, 1203.6, 1261.9	691.5, 755.9, 785.9, 807.2, 836.5, 885.3
	Base (GC-sIR)	1451.8, 1465.5, 1490.2, 1581.0, 1604.9	1019.1, 1048.2, 1072.6, 1084.2, 1104.4, 1133.3, 1170.9, 1203.1, 1261.5	694.9, 710.4, 757.6, 785.7, 806.9, 837.7, 882.1
7	HCl (ATR-IR)	1459.3, 1506.4, 1572.9	1041.5, 1094.2, 1134.8, 1167.8, 1208.5, 1261.0	700.4, 773.7, 786.3, 835.5, 885.0
	Base (ATR-IR)	1458.0, 1572.9	1038.0, 1084.5, 1106.4, 1164.5, 1220.1	686.4, 701.8, 773.5, 791.2, 833.6
	Base (GC-sIR)	1395.4, 1459.0, 1574.1	1038.7, 1082.6, 1106.6, 1113.3, 1164.7, 1220.5, 1254.3	704.7, 773.5, 792.6, 833.6, 867.6

* Also C–N stretch (aliphatic amines) from 1250–1020 cm⁻¹




** Also C–S stretches in this region

GC-sIR partial spectrum - overtone bands




Four adjacent hydrogens
on benzene ring



Three adjacent hydrogens
on benzene ring





Two adjacent hydrogens
and one isolated hydrogen
on benzene ring




Supporting Information – Drug Testing and Analysis

GC-sIR partial spectrum



Supporting Information – Drug Testing and Analysis

GC-sIR partial spectrum



Supporting Information – Drug Testing and Analysis

GC-sIR partial spectrum

